P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERAPY

P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERAPY

Bibliographic Details
Main Authors:	P. J. Walter, A. Schilhabel, P. Cramer, J. von Tresckow, S. Kohlscheen, K. Fischer, B. Eichhorst, S. Böttcher, M. Brüggemann, M. Kneba, M. Hallek, M. Ritgen
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845608.78318.49

Similar Items

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
by: Anke Schilhabel, et al.
Published: (2022-10-01)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01)

The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System
by: Mirjam van der Burg, et al.
Published: (2019-03-01)

Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels
by: Łukasz Sędek, et al.
Published: (2022-01-01)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
by: Moritz Fürstenau, et al.
Published: (2019-10-01)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
by: Natali Pflug, et al.
Published: (2021-12-01)

CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68.1.
by: Cerundolo, V, et al.
Published: (1991)

Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients—A EuroFlow Study
by: Anne E. Bras, et al.
Published: (2022-04-01)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

Dissection of the Pre-Germinal Center B-Cell Maturation Pathway in Common Variable Immunodeficiency Based on Standardized Flow Cytometric EuroFlow Tools
by: Lucía del Pino-Molina, et al.
Published: (2021-02-01)

Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
by: Vijay Singh, et al.
Published: (2014-01-01)

Celebrating 20 Years of IGHV Mutation Analysis in CLL
by: Nicholas Chiorazzi, et al.
Published: (2020-02-01)

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
by: Shlomo Elias, et al.
Published: (2018-06-01)

Value of CD11a and CD18 in flow cytometric immunophenotypic diagnosis of acute promyelocytic leukemia
by: Azza M S El Danasoury, et al.
Published: (2015-01-01)

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
by: William K Decker, et al.
Published: (2012-01-01)

Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood.
by: Mendes, R, et al.
Published: (2000)

Flow Cytometric Analysis of Leishmania Reactive CD4+/CD8+ Lymphocyte Proliferation in Cutaneous Leishmaniasis
by: M Nateghi Rostami, et al.
Published: (2008-12-01)

Flow Cytometric Analysis of Leishmania Reactive CD4+/CD8+ Lymphocyte Proliferation in Cutaneous Leishmaniasis
by: H Keshavarz, et al.
Published: (2008-12-01)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON-CLL B-CELL NON-HODGKIN LYMPHOMA
by: Sitaram Ghogale, et al.
Published: (2023-08-01)

Different expression of CD180, CD284 and CD14 receptors on the CD19+ subpopulation of normal and B-CLL lymphocytes.
by: Barbara Marzec-Kotarska, et al.
Published: (2010-05-01)

Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+
by: ZHAO Weihong, HUANG Bintao, LIU Rui, XIANG Caixia
Published: (2023-09-01)

Increased expression of CD20 and CD45 and diminished expression of CD19 are features of follicular lymphoma
by: Liu Q, et al.
Published: (2013-05-01)

CD160 receptor in CLL: Current state and future avenues
by: Loubna Oumeslakht, et al.
Published: (2022-11-01)

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
by: Edmund A Rossi, et al.
Published: (2014-01-01)

PB1866: RESPONSE TO NOVEL ANTI CD20 ANTIBODY AND BCL2 INHIBITOR IN A PATIENT WITH CLL AND MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH LEUKEMIC KIDNEY INFILTRATION AND REVIEW OF LITERATURE
by: J. G. Goanta, et al.
Published: (2022-06-01)

Flow Cytometric Determination of Neutrophil CD64 (nCD64) in Children with Community Acquired Pneumonia
by: Abdelhakeem Abdelmohsen, et al.
Published: (2019-08-01)

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people
by: Özcelik Dennis, et al.
Published: (2008-07-01)

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
by: Mitchell Evers, et al.
Published: (2020-01-01)

STUDY OF THE IMMUNOLOGICAL MARKERS CD49d AND CD38 IN EARLY-STAGE B-CLL PATIENTS
by: Vanya Popova, et al.
Published: (2018-01-01)

Expression of D20-40 and CD in patients with colorectal carcinoma
by: Basim M. Kashman, et al.
Published: (2012-01-01)

Anti-CD20 monoclonal antibodies: reviewing a revolution
by: J. M. L. Casan, et al.
Published: (2018-12-01)

Anti-CD20: tales of identical twins?
by: Schuh, A
Published: (2011)

Britannica CD 2.0 [cakera padat]
Published: (1995)

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
by: Greaves, P, et al.
Published: (2013)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
by: Florian Simon, et al.
Published: (2023-08-01)

Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)
by: V. Bruzzese, et al.
Published: (2011-06-01)

CD4 and CD20 as important immune markers in patients with pulmonary tuberculosis
by: Kamoona Firas Mohammad Hussein, et al.
Published: (2023-01-01)

Distribution of CD8 and CD20 lymphocytes in chronic periapical inflammatory lesions
by: Philippi Christine Kalvelage, et al.
Published: (2003-01-01)

Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms
by: Elissandra Machado Arlindo, et al.